DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
Authors
Keywords
Dipeptidyl peptidase 4 inhibitors, Systematic reviews, Type 2 diabetes mellitus, AMSTAR, GRADE
Journal
ACTA DIABETOLOGICA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-01
DOI
10.1007/s00592-018-1164-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The methodological and reporting quality of systematic reviews from China and the USA are similar
- (2017) Jinhui Tian et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes
- (2017) Mingxing Li et al. MEDICINE
- Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis
- (2017) Wen-Qin Guo et al. VALUE IN HEALTH
- Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
- (2017) Pravesh Kumar Bundhun et al. BMC Pharmacology & Toxicology
- Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2017) Stephen Kay et al. Diabetes Therapy
- Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2017) Stephen Kay et al. Diabetes Therapy
- Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials
- (2016) Islam Y. Elgendy et al. American Journal of Cardiovascular Drugs
- Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis
- (2016) Patricia M. Howse et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis
- (2016) Se Hee Min et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials
- (2016) Tiansheng Wang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease
- (2016) Hiroyuki Kamiya Hemodialysis International
- Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
- (2016) Amartya Kundu et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
- (2016) J. Kongwatcharapong et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts
- (2016) Roland E. Schmieder et al. JACC-Cardiovascular Interventions
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review
- (2016) Shishi Xu et al. POSTGRADUATE MEDICINE
- Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis
- (2016) Huai Heng Loh et al. Primary Care Diabetes
- Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients
- (2015) G. McInnes et al. DIABETES OBESITY & METABOLISM
- DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials
- (2015) Wenjia Yang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial
- (2015) J.-B. Zhou et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
- (2015) LIQIONG HOU et al. Experimental and Therapeutic Medicine
- A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
- (2015) K. Esposito et al. BMJ Open
- The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type-2 diabetes mellitus-a meta-analysis
- (2014) Xia Liu et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Comparison of GLP-1 Analogues versus Sitagliptin in the Management of Type 2 Diabetes: Systematic Review and Meta-Analysis of Head-to-Head Studies
- (2014) Tiansheng Wang et al. PLoS One
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis
- (2014) Dongsheng Cheng et al. PLoS One
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors: Systematic Review and Meta-Analysis
- (2014) A. Pérez et al. VALUE IN HEALTH
- Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis
- (2014) Andrea C Tricco et al. BMJ Open
- Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
- (2014) K. Esposito et al. BMJ Open
- Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes
- (2013) Saurav Chatterjee et al. ANNALS OF INTERNAL MEDICINE
- Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis
- (2013) Qiang Du et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis
- (2013) D. Wu et al. DIABETES OBESITY & METABOLISM
- Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
- (2013) Yifei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
- (2013) Asres Berhan et al. BMC Endocrine Disorders
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
- (2012) Haesuk Park et al. ANNALS OF PHARMACOTHERAPY
- Overview of Methodological Quality of Systematic Reviews about Gastric Cancer Risk and Protective Factors
- (2012) Lun Li et al. Asian Pacific Journal of Cancer Prevention
- Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers
- (2012) Hyun-Ju Seo et al. BMC Medical Research Methodology
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
- (2012) D. Singh-Franco et al. DIABETES OBESITY & METABOLISM
- Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
- (2012) K. Gooßen et al. DIABETES OBESITY & METABOLISM
- Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis
- (2011) K. R. Gerrald et al. DIABETES OBESITY & METABOLISM
- The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- (2011) L. Cai et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Effects of clinical decision-support systems on practitioner performance and patient outcomes: a synthesis of high-quality systematic review findings
- (2011) M. W. M. Jaspers et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research
- (2010) Susan Armijo-Olivo et al. JOURNAL OF EVALUATION IN CLINICAL PRACTICE
- Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now